1. Role of therapeutic drug monitoring of intravenous Busulfan for prevention of sinusoidal obstructive syndrome in children.
- Author
-
Gurlek Gokcebay, Dilek, Arman Bilir, Ozlem, Şahin, Seda, Ok Bozkaya, İkbal, and Ozbek, Namık Yasar
- Subjects
DRUG monitoring ,HEMATOPOIETIC stem cell transplantation ,BONE marrow transplantation ,SYNDROMES in children ,BUSULFAN - Abstract
Background: Therapeutic drug monitoring (TDM) of intravenous busulfan (Bu) has been recommended for safe engraftment and decreased toxicity in children undergoing hematopoietic stem cell transplantation (HSCT). This study aims to compare HSCT‐related outcomes, such as acute or chronic graft‐versus‐host disease (GvHD), sinusoidal obstructive syndrome (SOS), event‐free survival (EFS), and overall survival (OS) in children with and without TDM for busulfan. Methods: This retrospective study conducted between February 2012 and February 2021 at our Bone Marrow Transplantation Unit included 172 patients (34% girls) with a median age of 4.70 years (IQR 2.41–10.01). Group A consisted of 46 patients whose Bu doses were adjusted according to actual body weight, and group B consisted of 126 patients whose Bu dose adjustments made according to TDM. Results: Totally, 32 patients (19%) developed moderate or severe SOS. The incidence of SOS was significantly higher in the group without TDM (29% vs. 15%, p =.041). A multivariable analysis showed that the presence of acute GvHD and one alkylating drug‐containing conditioning regimen compared with two or three were associated with SOS (p =.03 and p =.002, respectively). In patients with TDM, cumulative Bu dose and area under curve also were not associated with SOS. Other HSCT‐related outcomes such as acute or chronic GvHD, relapse and graft rejection rates, OS and EFS rates did not differ between the groups. Conclusions: TDM and making dose adjustments with Bayesian forecasting over four days of Bu therapy optimizes exposure and reduces the risk of SOS in children undergoing HSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF